Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · IEX Real-Time Price · USD
237.83
+1.13 (0.48%)
At close: Jul 19, 2024, 4:00 PM
237.85
+0.02 (0.01%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,100 employees as of December 31, 2023. The number of employees increased by 98 or 4.90% compared to the previous year.
Employees
2,100
Change (1Y)
98
Growth (1Y)
4.90%
Revenue / Employee
$953,969
Profits / Employee
-$158,131
Market Cap
30.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Centene | 67,000 |
GE HealthCare Technologies | 51,000 |
ICON PLC | 41,100 |
Agilent Technologies | 18,100 |
Mettler-Toledo International | 17,300 |
IDEXX Laboratories | 11,000 |
ResMed | 10,140 |
Biogen | 7,570 |
ALNY News
- 4 days ago - Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results - Business Wire
- 24 days ago - What's Next For Alnylam Stock After A 60% Rise In A Week? - Forbes
- 27 days ago - Alnylam Stock Soars on Strong Results in Heart Drug Study - Investopedia
- 27 days ago - Alnylam Pharmaceuticals reports promising heart disease trial results - Invezz
- 27 days ago - Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds - Forbes
- 27 days ago - Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge - Benzinga
- 27 days ago - Alnylam's stock surges as heart drug vies with a Pfizer blockbuster - Market Watch
- 27 days ago - Alnylam Stock Soars After Positive Results From Heart Disease Study - Barrons